A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis (PN)

Main inclusion criteria:

  1. Clinical diagnosis of PN for at least 6 months with Pruriginous nodular lesions on upper limbs, trunk, and/or lower limbs. At least 20 nodules on the entire body with a bilateral distribution with IGA score ≥ 3.
  2. Severe pruritus defined as ≥ 7 on the PP NRS.
  3. Lack of any other primary pruritic skin condition.
Sponsor(s)
Galderma
Principal Investigator(s)
Dr. Jonathan Silverberg
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

1 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.